What guidance has AbbVie issued on next quarter's earnings? Abbvie stock price has put up an impressive performance in 2022. AbbVie's post-Humira LOE plans are not riskless, and its targets are ambitious, but nevertheless I see no harm in picking up shares in the Pharma at the current price, accepting a generous 4% dividend, and likely benefitting from share repurchases and a steadily growing share price until 2030. On average, analysts rate AbbVie stock as a buy. AbbVie Stock: A Blue Chip You Cannot Afford To Miss, Yield 4.1% All times are ET. Free Stock Analysis Report: See The True Value of Any Stock, The Best Strategy For Your Small Trading Account. Morningstar: 2019 Morningstar, Inc. All Rights Reserved. Trading CFDs is high risk and is not suitable for everyone. That reflects uncertainty about what the future holds for AbbVie. AbbVie product revenues by quarter and year since FY20. (JPM Healthcare conference presentation), Skyrizi's performance has been particularly eye-catching. In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. The median. All rights reserved. I have no business relationship with any company whose stock is mentioned in this article. To date, the company had invested more than $50 billion into research through more than 250 partnerships. This suggests a possible upside of 3.8% from the stock's current price. 580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over pastmonths for detail. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. The median estimate represents a +5.72% increase from the last price of 156.07. 164.71 0.00 0.00%. As per management's guidance, I am modelling for $5.7bn of revenues in 2023, with growth beginning to accelerate substantially from 2025 / 26 onwards. Abbvie Stock Forecast 2023, 2024, 2025, 2030 - Stock in US 8.05% AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 3.83%. Receive regular, detailed analysis focused on biotech and healthcare stocks. I'm on twitter @edmundingham. Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. View which stocks are hot on social media with MarketBeat's trending stocks report. That makes companies like AbbVie generally very attractive to investors although it should be noted that AbbVie carries a very high level of debt which stood at >$60bn as of Q322 - more or less the amount the company paid to acquire Allergan. Sales of the drug reached $19.9bn in 2018 and were $19.2bn, $19.8bn and $20.6bn in 2019, 2020, and 2021 respectively. Since then, however, the stock price has fallen 18% to. z o.o., AbbVie Productos Farmacuticos Limitada, AbbVie Products LLC, AbbVie Promoo L.da, AbbVie Pte. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The company didn't offer a . The lowest target is $136.35 and the highest is $210. The shining star in the aesthetics business is Botox, which increased sales by 45% year over year to $477 million in the first quarter of 2021. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tbbi lalar Sanayi ve Ticaret Limited irketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundacin AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC. RHHBY vs. ABBV: Which Stock Is the Better Value Option? The S&P 500 (US500) lost 9.1%, the Dow Jones (US30) slid 9.7%, and the Nasdaq Composite fell 23% during the same period. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Get daily stock ideas from top-performing Wall Street analysts. Based on earnings estimates, AbbVie will have a dividend payout ratio of 54.11% next year. Whether these factors make ABBV a good investment for you or not will depend on your portfolio composition, investment goals and risk profile, among other factors. The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. All rights reserved. What other stocks do shareholders of AbbVie own? AbbVie has a P/B Ratio of 15.97. One share of ABBV stock can currently be purchased for approximately $156.06. AbbVie is led by CEO and Chairman Rick Gonzalez - likely the only Pharma CEO who lacks a college degree - who has successfully defended Humira from generic drug competition by adopting a controversial strategy of continually applying for new patents related to minor changes in manufacturing methods or administration, often referred to as a "patent thicket". Allergan was a troubled company in many ways, but there is no doubting the strength of its products and pipeline. psoriatic arthritis at a lower dose, again with a comparable safety profile, and has also won approval in a field where Humira has not, namely Atopic Dermatitis. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. ABBV-916 is therefore a real opportunity for AbbVie to develop a more effective and safer drug in the same class and claim a sizeable share of a 6m patient market. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. AbbVie Oncology Division Forward Revenue Projections (my table and assumtpions). What intrigues here is the possibility of RGX-314, an anti-VEGF gene therapy that Gonzalez believes "has the potential to be a one-time treatment for wet AMD, diabetic retinopathy and other chronic retinal conditions". AbbVie's stock is owned by many different institutional and retail investors. GSK Stock Forecast 2023 - 2025 - 2030 | StockForecast.com The company's lead asset - all-time best selling immunology drug Humira - finally loses patent protection this year and sales will enter a period of terminal decline. While some of the gains are due to investor perception that it is a strong company, some view ABBV as a defensive stock, with most of the other stocks in the sector also doing well. AT&T Inc. (T) stock forecast and price target Find the latest AT&T Inc. T analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. AbbVie Stock Crumbles On Mixed Earnings, Slashes 2022 Earnings Outlook Abbvie Stock Forecast | Is Abbvie a Good Stock to Buy? - Capital Your current $100 investment may be up to $188.28 in 2028. approvals of Humira, Skyrizi, Rinvoq (AbbVie JPM Healthcare conference presentation). What is a Good Dividend Yield? AbbVie saw a increase in short interest in February. Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. The companys full-year adjusted diluted EPS guidance excluded any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of the year, as both cannot be reliably forecasted. Duodopa is approved for Parkinson's Disease but Gonzalez believes that the subcutaneous non-surgical delivery system of candidate ABBV951 can "significantly expand the patient population currently addressed by Duopa", and sees the drug as yet another future blockbuster. losed Joint Stock Company FinTech Solutions, Fidelity NASDAQ Composite Index Tracking Stock Fund, Abbvie stock price analysis: Past year performance, Abbvie fundamental analysis: Q1 2022 earnings, Abbvie stock forecast: Company guidance and analysts predictions. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. Not only do these companies pay handsome dividends, they typically grow revenues every year and generate wide profit margins which leads to share price upside. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. ABBV - AbbVie Stock Prediction 2025 - 2030 When looking for ABBV stock forecasts, it's important to bear in mind that analysts' forecasts can be wrong. The important point here is that physicians will not necessarily be under any pressure to switch patients from Humira to a biosimilar, given, as Gonzalez puts it: there won't be any difference between the biosimilar and Humira from a co-pay standpoint or any kind of a step editing. Payout ratios above 75% are not desirable because they may not be sustainable. When looking for ABBV stock forecasts, its important to bear in mind that analysts forecasts can be wrong. Projections are based on making fundamental and technical studies of the ABBV stock price performance. (ABBV), MarketBeat Week in Review 2/13 - 2/17 (ABBV), The 3 Best Pharma Stocks to Buy for Big Gains in 2023 (ABBV), How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula (ABBV), AbbVie Has a Mixed Outlook After Mixed Earnings, Q4 2022 AdTheorent Holding Company Inc Earnings Call. The company earns $11.84 billion in net income (profit) each year or $6.61 on an earnings per share basis. I have plugged my revenue expectations into this table knowing that they closely match AbbVie management's own expectations based on what they have said in public. Different trading strategies will suit different investment goals with short or long-term focus. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. In other words, management believes the LOE of Humira - despite it being the world's best-selling drug - will not hinder growth at the company. Always conduct your own due diligence before investing. What is ABBV's Earnings Per Share (EPS) forecast for 2023-2025? I had felt this could be an issue for Skyrizi and Rinvoq, given it is rare for a drug to be as dominant as Humira was, but although the level of competition is fierce, both drugs are more than meeting expectations, and with the entire auto-immune market worth as much as $45 - $50bn, it does seem possible that Skyrizi and Rinvoq could one day generate >$20bn revenues between them, as management hopes. If you have an ad-blocker enabled you may be blocked from proceeding. ABBV has several positive factors pushing its price performance. The surge in revenues can primarily be attributed to its Allergan. AbbVie does not have the funds to pursue any large M&A deals, but it does not need to either, given the strength of its pipeline and products. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska druba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacuticos S.A. de C.V., AbbVie Farmacutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S. r.l., AbbVie Investments Limited, AbbVie Investments S. r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementr GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Bringing RGX314 would be a coup for AbbVie although I am forecasting for only $2bn in peak revenues in 2030 as a hedge against the risk that this candidate does not make it to market on safety grounds. With Skyrizi and Rinviq - two assets developed in-house - performing so well, however, perhaps we should give management the benefit of the doubt. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. High institutional ownership can be a signal of strong market trust in this company. Within the oncology division sales of Imbruvica fell 17% year-on-year. At their peak, according to a slide from AbbVie's presentation at the JPMorgan (JPM), these 2 drugs are expected to generate more revenues than Humira at its peak. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock. Forecast target price for 03-06-2023: $ 152.58. The Abbvie stock forecast for 2025 had the price at $259.018. Drug pricing is another issue - there is bipartisan, and international pressure on US Pharmas to reduce drug pricing, particularly outside of the US. The other major plus is probably the performance of the neuroscience divisions, where as we can see, Botox (indicated for migraine treatment), atypical antipsychotic Vraylar, migraine therapy Ubrelvy and newly launched Qulipta, an oral CGRP inhibitor indicated for chronic migraine all delivered good sales growth. AbbVie has received a consensus rating of Hold. As with debt, if approval and revenue targets aren't met, it can quickly result in a loss of faith in the company. See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. AbbVie Stock Forecast 2023 - 2025 - 2030 | StockForecast.com The current consensus among 24 polled investment analysts is to Buy stock in Abbvie Inc. This indicates that AbbVie will be able to sustain or increase its dividend. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. It pays a dividend yield of 3.83%, putting its dividend yield in the top 25% of dividend-paying stocks. In this article we take a closer look at the Abbvie stock forecast, after analysing the firms latest earnings, price moving news and analyst comments. The average ABBVIE INC stock forecast 2023 represents a 1.86% increase from the last price of $153.729995727539. (AbbVie JPM Healthcare conference presentation). Sign in to your free account to enjoy all that MarketBeat has to offer. Please log in to your account or sign up in order to add this asset to your watchlist. We expect proof-of-concept data from roughly a dozen additional early stage oncology opportunities over the next couple of years. Wallet Investor suggested that the price could hit $300.386 in June 2027. According to 23 major analysts, AbbVie's Fair Value will fall by 5.43% in the next year, reaching $122.98. The company issued revenue guidance of -. Forecast . Slide from JPM Conference 2022 presentation. That is interesting to me as I think it suggests management will need to commercialize more assets if it wants to hit that target. Venclexta - a "first-in-class BCL-2 inhibitor for multiple hematological malignancies", according to Gonzalez, is forecast for strong growth, whilst Gonzalez has name checked 3 new drugs he expects to be approved by 2026. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049. Most stock quote data provided by BATS. About the AbbVie, Inc. stock forecast. ABBV Stock Forecast Price Target for 2024 TradingView In my modeling table above, I estimate Humira sales will decline by 25% between 2022 and 2023, to ~$16bn, although some of that lost revenue will be gobbled up by Skyrizi/Rinvoq. My No. The official website for the company is www.abbvie.com. In the next year, analysts expect Free Cash Flow to reach $26.97B - an increase of 58.68%. Both Leqembi and Donanemab are potential $5bn - $10bn selling assets, but both drugs still have safety questions to answer and not certain to be made eligible for reimbursement. The consensus rating was moderate buy based on 16 analysts ratings, with 10 recommending buy, five hold and sell. The "King Of Quants" sees 10X potential Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S. r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Receive regular, detailed analysis focused on biotech and healthcare stocks. As we look beyond 2025, we expect combined sales for Skyrizi and Rinvoq to exceed the peak revenues achieved by Humira, which was more than $21 billion. In the next year, analysts predict that Revenue will reach C$253.83M - an increase of 3.50%. That led to an overall 6% year-on-year gain of 6%, and a 13% sequential gain. To summarize, although AbbVie does not have the same clout in oncology as it does in immunology - as evidenced perhaps by the declining sales of Imbruvica - it is clearly an area of focus for management. Kateryna Onyshchuk/iStock via Getty Images. That was below AbbVie stock analysts' view for $14.16. After creating the income statement I prepare the discounted cash flow/EBITDA multiple analysis. As of 2023 February 22, Wednesday current price of ABBV stock is 151.340$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Abbvie stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. AbbVie has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. I haven't included Epcoritamab sales in my forecasts this time, but I hope to adjust the table before Q3'22 results are announced. With AbbVie seemingly very confident of approvals for all 3 of these drugs, and Gonzalez suggesting they could form the basis of a "$6 billion kind of franchise" I have modelled for such an outcome by 2030. How often does AbbVie pay dividends? Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions. Always do your own research on a stocks price performance and predictions before making an investment. As of 30 June, analysts price predictions compiled by MarketBeats and long-term forecasts by Wallet Investor projected that the ABBV stock price could rise. The development of these 2 drugs has been very quick by drug development standards, and to date both have performed exceptionally well. ABBV Stock 12 Months Forecast. Please disable your ad-blocker and refresh. Get short term trading ideas from the MarketBeat Idea Engine. The five-year dividend growth rate is just below 18%. The AbbVie of today has 5 thriving divisions - Immunology, Oncology, Neuroscience, Aesthetics, and Eye Care - with the latter 3 divisions acquired from Allergan as part of AbbVie's $63bn takeover of that company. Bhd., AbbVie Sp. Since then, ABBV stock has decreased by 3.4% and is now trading at $156.06. In the last four years, Johnson & Johnson's Free Cash Flow has fallen from $18.53B to $17.00B - a 8.28% decrease. That figure suggests a forward Price to Earnings ("P/E") ratio of ~10x, which is well below the US Big Pharma sector average of ~23x, although it should be noted that the GAAP/non-adjusted EPS may be only significantly lower than the adjusted figure, based on adjusted EPS of $6.52 across H1'22, and GAAP EPS of $3.03 over the same period. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! As such, I have decreased my own expectations for 2022 based on simply doubling H1'22 revenues to get a FY22 figure, and downgrading growth expectations to 3% per annum until 2026. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. Capital Com Australia Pty Ltd (ABN 47 625 601 489) is a company registered in Australia and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL 513393. This included an unfavourable impact of $0.08 a share related to acquired in-process research and development (IPR&D) and milestones expenses incurred during the March quarter. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions. Please disable your ad-blocker and refresh. View AbbVie's Short Interest. The average price target is $163.64 with a high forecast of $190.00 and a low forecast of $133.00. There has been a raft of price-moving news for Abbvie, which may positively affect the stock price. 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. Pessimistic target level: 151.42 Optimistic target level: 154.48 ABBV (ABBV) Monthly Stock Prediction for 2023 Full forecast for 2023 AbbVie forecast for this year AbbVie Aesthetics / Neurology revenues forecasts to 2030 (my table and assumptions) . AbbVie's success - as its shareholders will doubtless be aware - stems from the runaway success of its immunology drug Humira, which is indicated for a range of autoimmune conditions, including Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, Hidradenitis Suppurativa and Ankylosing spondylitis.